Non Hodgkin's Lymphoma Refractory/Relapsed
Oncology·MeSH: Recurrence
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
4 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| N803 | ImmunityBio, Inc. (IBRX) |
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| Fludarabine | ImmunityBio, Inc. (IBRX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Non Hodgkin's Lymphoma Refractory/Relapsed?
BioSniper tracks 4 drugs in development for Non Hodgkin's Lymphoma Refractory/Relapsed across 1 company.
How many clinical trials target Non Hodgkin's Lymphoma Refractory/Relapsed?
There are 1 clinical trial targeting Non Hodgkin's Lymphoma Refractory/Relapsed tracked by BioSniper.
What is the prevalence of Non Hodgkin's Lymphoma Refractory/Relapsed?
The estimated prevalence of Non Hodgkin's Lymphoma Refractory/Relapsed is approximately 56.0 per 100,000 population.
Deep-dive into Non Hodgkin's Lymphoma Refractory/Relapsed
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis